News tagged with gleevec

Related topics: cancer drugs · drug

New hope for a type 2 diabetes cure

The cancer treatment drug Imatinib, otherwise known as Gleevec is approved to treat various forms of cancer, mostly notably chronic myeloid leukemia (CML). However, researchers have stumbled onto another possible use for ...

Mar 28, 2016
popularity302 comments 1

Cancer drug shows promise for treating scleroderma

A drug approved to treat certain types of cancer has shown promising results in the treatment of patients with scleroderma, according to results from an open-label Phase II trial. While the drug's efficacy must be demonstrated ...

Mar 28, 2011
popularity0 comments 0

Finding key to cancer drug Gleevec's limitations

University of Michigan researchers have developed an animal model that provides strong evidence why imatinib, marketed as Gleevec, helps patients with chronic myeloid leukemia survive longer, but does not keep the disease ...

Aug 05, 2009
popularity0 comments 1

A lethal cancer knocked down by one-two drug punch

In the battle against cancer, allies can come from unexpected sources. Research at The Jackson Laboratory has yielded a new approach to treating leukemia, one that targets leukemia-proliferating cells with drugs that are ...

Jun 07, 2009
popularity0 comments 2

Drug could provide first treatment for scleroderma

Investigators have identified a drug that is currently approved to treat certain types of cancer, Gleevec, that could provide the first treatment for scleroderma, a chronic connective tissue disease for which a treatment ...

Oct 18, 2009
popularity0 comments 1

Imatinib

Imatinib (originally STI571) is a drug used to treat certain types of cancer. It is currently marketed by Novartis as Gleevec (USA) or Glivec (Europe/Australia/Latin America) as its mesylate salt, imatinib mesilate (INN). It is used in treating chronic myelogenous leukemia (CML), gastrointestinal stromal tumors (GISTs) and some other diseases. By 2011, Gleevec has been FDA approved to treat ten different cancers. In CML, the tyrosine kinase enzyme ABL is locked in its activated form. It induces the abnormal phenotypes of CML: excessive proliferation and high white blood cell count. Imatinib binds to the site of tyrosine kinase activity, and prevents its activity, thereby causing tumor cell apoptosis.

Imatinib is the first member of a new class of agents that act by specifically inhibiting a certain enzyme that is characteristic of a particular cancer cell, rather than non-specifically inhibiting and killing all rapidly dividing cells, and served as a model for other targeted therapy modalities through tyrosine kinase inhibition.

This text uses material from Wikipedia, licensed under CC BY-SA

Subscribe to rss feed